Eidos Therapeutics (EIDX) approached by BridgeBio Pharma (BBIO)

  • August 9, 2019


StockEidos Therapeutics, Inc.SymbolEIDX
Date Announced08/08/2019Source Press Release
TypeUnsolicited BidAcquiring Company/Person BridgeBio Pharma, Inc.
Date of Confirmation: 10/05/2020Price at Confirmation: $73.01
Potential Profit: 127.73%Annualized Profit: 109.96%

BridgeBio Pharma Inc. (BBIO) is pleased to submit this non-binding proposal to acquire all of the outstanding shares of stock of Eidos Therapeutics, Inc. (EIDX) that are not owned by BridgeBio for a fixed exchange ratio of 1.30 BridgeBio shares for each share of Eidos.


September 12, 2019: Eidos Therapeutics, Inc. (EIDX) announced today that the Special Committee of its Board of Directors unanimously rejected the non-binding proposal dated August 8, 2019 from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder, to purchase all of the outstanding common stock of the Company not already owned by BridgeBio for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos common stock.

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.